The FDA's New Bayesian Guidance and the Hardest Question in Parkinson's Trials2026-03-24 · 6 min read
The FDA's new Bayesian guidance changes what clinical trials can ask and answer. For Parkinson's disease, where proving disease modification has always been the hardest problem, this matters more than most.
What a Week of Real-World Walking Data Reveals About Parkinson's Disease2026-03-17 · 6 min read
The Mobilise-D consortium validated 24 digital mobility outcomes in 601 people with Parkinson's disease across five European sites. The data make a careful case for rethinking how trials measure what matters.
The Wearable Worked. The Outcomes Didn't Move.2026-03-09 · 4 min read
A 35-center randomized trial tested whether wearable-guided medication adjustment improved outcomes in Parkinson's disease. The result opens questions about where these tools work best.
The Implementation Problem in Parkinson's AI: Lessons from Cardiology2026-02-27 · 5 min read
Why real-world workflow adoption, not just model performance, will determine impact for Parkinson's AI in primary care.
AI in Parkinson's Disease Diagnosis: Context Determines the Standard2026-02-19 · 4 min read
Why the clinical value of AI in Parkinson's disease diagnosis depends on context, intended use, and measurable decision impact.